Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/32874
Tipo
ArtículoDerechos de autor
Acceso restringido
Fecha del embargo
2050-01-01
Colecciones
Metadatos
Mostrar el registro completo del ítem
DEVELOPMENT OF ANTIBODY BIOMARKERS OF LONG TERM AND RECENT DENGUE VIRUS INFECTIONS
IgG subclasses
IgG3
Long term
Recent infection
Virus exposure
Biomarker
Adulto
Envelhecido
Idoso, 80 anos ou mais
Anticorpos virais / sangue
Biomarcadores / sangue
Brasil
Criança
Criança, pré-escolar
Dengue / diagnóstico
Dengue / imunologia
Vírus da Dengue / imunologia
Ensaio de Imunoadsorção Enzimática
Fêmea
Humanos
Imunoglobulina A / sangue
Imunoglobulina G / sangue
Imunoglobulina M / sangue
Infantil
Recém-Nascido
Estudos longitudinais
Masculino
Meia idade
Fatores de Tempo
Proteínas Não-estruturais Virais / imunologia
Adulto jovem
Autor
Afiliación
University of Pittsburgh. Graduate School of Public Health and Center for Vaccine Research. Pittsburgh, PA, USA.
One Discovery Drive. Sanofi Pasteur. Swiftwater, PA, USA.
Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Recife, PE, Brasil.
Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Recife, PE, Brasil / University of Pernambuco. School of Medical Science. Recife, PE, Brazil.
One Discovery Drive. Sanofi Pasteur. Swiftwater, PA, USA.
DST-NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA). Stellenbosch, Western Cape, South Africa.
DST-NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA). Stellenbosch, Western Cape, South Africa.
One Discovery Drive. Sanofi Pasteur. Swiftwater, PA, USA.
University of Pittsburgh. Graduate School of Public Health and Center for Vaccine Research. Pittsburgh, PA, USA.
University of Pittsburgh. Graduate School of Public Health and Center for Vaccine Research. Pittsburgh, PA, USA / Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Recife, PE, Brasil.
One Discovery Drive. Sanofi Pasteur. Swiftwater, PA, USA.
Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Recife, PE, Brasil.
Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Recife, PE, Brasil / University of Pernambuco. School of Medical Science. Recife, PE, Brazil.
One Discovery Drive. Sanofi Pasteur. Swiftwater, PA, USA.
DST-NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA). Stellenbosch, Western Cape, South Africa.
DST-NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA). Stellenbosch, Western Cape, South Africa.
One Discovery Drive. Sanofi Pasteur. Swiftwater, PA, USA.
University of Pittsburgh. Graduate School of Public Health and Center for Vaccine Research. Pittsburgh, PA, USA.
University of Pittsburgh. Graduate School of Public Health and Center for Vaccine Research. Pittsburgh, PA, USA / Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Recife, PE, Brasil.
Resumen en ingles
Dengue virus (DENV) infections elicit antibody responses to the non-structural protein 1 (NS1) that are associated with protection against disease. However, the antibody isotypes and subclasses involved, and their kinetics have not been extensively studied. We characterized the antibody responses to DENV NS1 by enzyme-linked immunosorbent assay (ELISA) in a longitudinal cohort of 266 confirmed dengue cases in Recife, Northeast Brazil. Samples were collected during the febrile phase and up to over 3 years after onset of symptoms. The antibodies investigated [IgA, IgM, total IgG (all subclasses measured together) and each subclass (IgG2, IgG3 and IgG4) measured separately] had distinct kinetic profiles following primary or secondary DENV infections. Of interest, most of these antibodies were consistently detected greater than 6 months after onset of symptoms, except for IgG3. Anti-dengue NS1-specific IgG was consistently detected from the acute phase to beyond 3 years after symptom onset. In contrast, anti-dengue NS1-specific IgG3 was detected within the first week, peaked at week 2-3, and disappeared within 4-6 months after onset of symptoms. The mean duration of the IgG3 positive signal was 149 days (ranging from 126 to 172 days). In conclusion, anti-dengue NS1-specific IgG and IgG3 are potential biomarkers of long-term and recent (less than 6 months) DENV infections, respectively.
Palabras clave en ingles
AntibodyIgG subclasses
IgG3
Long term
Recent infection
Virus exposure
Biomarker
DeCS
AdolescenteAdulto
Envelhecido
Idoso, 80 anos ou mais
Anticorpos virais / sangue
Biomarcadores / sangue
Brasil
Criança
Criança, pré-escolar
Dengue / diagnóstico
Dengue / imunologia
Vírus da Dengue / imunologia
Ensaio de Imunoadsorção Enzimática
Fêmea
Humanos
Imunoglobulina A / sangue
Imunoglobulina G / sangue
Imunoglobulina M / sangue
Infantil
Recém-Nascido
Estudos longitudinais
Masculino
Meia idade
Fatores de Tempo
Proteínas Não-estruturais Virais / imunologia
Adulto jovem
Compartir